Barry Simon, M.D. – Chairman of the Board
Dr. Barry Simon is a healthcare executive with more than 30 years of experience spanning the public and private sectors. He currently serves as President and CAO at Nantkwest (NASDAQ: NK), an Immuno-therapeutics company, and from 2007-2015 served as its President and CEO. Since 2017, Dr. Simon has been serving as a Director for Viracta Therapeutics, a privately held oncology therapeutics company, and since 2015 has also been serving as President and CEO and Director for Brink Biologics, Inc., a privately held diagnostics and laboratory services provider specializing in monoclonal antibody and vaccine testing. Dr. Simon previously held various vice president, senior level executive and advisory positions at Roche Labs, F. Hoffmann-La Roche (VTX: ROG), Connetics Corp. (NASDAQ: CNCT), Immunomedics (NASDAQ: IMMU), Immusol Inc., NorthSound Capital, LLC, and HealthPro BioVentures. He has broad experience with product and portfolio divestitures and acquisitions, strategic licensing and joint ventures in addition to commercial product launches, IND and BLA regulatory filings, human-enabling programs, manufacturing, quality control and life cycle management. Dr. Simon attended corporate training programs by the London School of Business and the Amos Tuck School of Business at Dartmouth College. He trained clinically in infectious diseases, anesthesiology and internal medicine and received his M.D. from the SUNY Downstate, Health Sciences Center in New York.
Peter Kiener, D.Phil.
Peter Kiener has deep experience in both biologics and immunotherapy, and is the former Chief Scientific Officer at Sucampo. Prior to joining Sucampo, he served as CSO of Ambrx Inc., a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates. Prior to Ambrx, Dr. Kiener was President and Co-founder of Zyngenia Inc., an early-stage biopharmaceutical company. He also held leadership roles at MedImmune LLC, the global biologics arm of AstraZeneca, including Executive Vice President and Global Head of Biologics Research and Development, Senior Vice President and Head of Global Research, and Vice President of Research. He also worked on biologics for Bristol-Myers Squibb prior to his work at MedImmune. Dr. Kiener has served on the scientific advisory boards of KAI Pharmaceuticals Inc., Genocea Biosciences Inc., NKT Therapeutics Inc. and VLST Corporation and as a member of the Board of Directors of Receptor BioLogix Inc., Synovex Corporation and Virdante Pharmaceuticals Inc. He has published more than 120 papers in peer-reviewed journals and is an inventor on more than 40 patents and patent applications. Dr. Kiener earned a bachelor’s degree in chemistry from the University of Lancaster and a doctorate of philosophy in biochemistry from the University of Oxford.
Fred Driscoll has more than 20 years of experience in financial management of life sciences companies, most recently as the Chief Financial Officer at Flexion Therapeutics, Inc., where he spearheaded an initial public offering in 2014. Prior to joining Flexion, he served as Chief Financial Officer at Novavax, Inc. from 2009 to 2013. From 2008 to 2009, Mr. Driscoll served as Chief Executive Officer of Genelabs Technologies, Inc., a publicly traded biopharmaceutical and diagnostics company later acquired by GlaxoSmithKline. Prior to serving as Chief Executive Officer of Genelabs he was the Chief Financial Officer from 2007 to 2008. From 2000 to 2006, Mr. Driscoll served as Chief Executive Officer at OXiGENE, Inc., where he also served as Chairman of the Board and Audit Committee Chair. He was also a member of the Audit Committee for Cynapsus Therapeutics, Inc., which was sold to Sunovion Pharmaceuticals in 2016. Mr. Driscoll earned a B.S. in accounting and finance from Bentley University. He is a member of the board of directors of Cellectar Biosciences, Inc., MEI Pharma, Inc. and NantKwest, Inc.
Frank Morich, M.D., Ph.D.
Dr. Frank Morich is a biopharmaceutical professional with more than 35 years of industry experience. He currently serves on the board of directors for MorphoSys (since May 2015) and served as a board member for Innate Pharma between 2004-2010, both clinical-stage biotechnology companies specializing in antibody development. Prior to focusing on board work, from 2011 to 2014, Dr. Morich served as Chief Commercial Officer at Takeda Pharmaceuticals, a global pharmaceutical company, and, from 2010 to 2011, he served as Executive Vice President, International Operations at Takeda. From 2008 to 2010, Dr. Morich served as Chief Executive Officer of NOXXON Pharma AG, a clinical-stage drug development company, and, from 2005 to 2007, he served as Chief Executive Officer and member of the board of directors of Innogenetics N.V., an international in vitro diagnostics company. Prior to that, Dr. Morich held several positions at Bayer, a global pharmaceutical and life sciences company, including member of the Board of Management of Bayer AG, Head of Global Product Development and Head of Research and Development. Dr. Morich holds an M.D. and Ph.D. from the University of Marburg where he specialized in immunology with a focus on monoclonal antibodies. He served as a military physician before moving to industry.
Aaron Fletcher, Ph.D.
Dr. Fletcher is managing director of Bios Partners, a life sciences venture firm based in Fort Worth, Texas and founded and serves as president of Bios Research, a financial services firm that provides public equity research in the healthcare space tailored to institutional firms. Bios Research provides fundamental healthcare industry research focused in the biotech and med-tech sub-sectors and through this research, Dr. Fletcher has a strong understanding of commercial viability in the marketplace. Dr. Fletcher holds a Ph.D. in biochemistry from Colorado State University and currently serves as a visiting professor at Dallas Baptist University. Dr. Fletcher has worked as an independent consultant for the biotech/healthcare equity industry for more than 10 years and has extensive experience at companies covering a variety of diagnostic and therapeutic areas including oncology.
Cameron Gray, Ph.D.
Cameron Gray has been a member of our board of directors since January 2015 and served as our Chief Executive Officer from June 2015 to August 2016. In December 2019, he founded Alcedo Capital. Dr. Gray was a Managing Director at MDB Capital Group from September 2013 to November 2019. Prior to joining MDB Capital Group, Dr. Gray served as Chief Executive Officer and a member of the board of directors of Endeavor IP, Inc., an intellectual property services and patent licensing company, from May 2013 through January 2014. Prior to that, he was Senior Vice President at ICAP Patent Brokerage, LLC, where he managed its life sciences and Asia Pacific businesses from January 2009 through January 2012. Dr. Gray has a J.D. from George Washington University School of Law, a Ph.D. in biophysics from the University of Virginia, and a B.A. in physics from Princeton University.